Showing 1391-1400 of 5771 results for "".
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-positive-results-from-phase-3-trial-of-once-daily-ocs-01-for-treatment-of-inflammation-and-pain-following-cataract-surgery/2482221/Oculis announced positive results from the phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS annual meeting in Boston. Eric Donnenfeld, MD, presented the “Once Daily OCS-01, an OPTIREACH F
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- Nidek Announces Winners of the 4th Annual Image of the Year Awardhttps://modernod.com/news/nidek-announces-winners-of-the-4th-annual-image-of-the-year-award/2482217/Nidek has announced the winners of the 4th annual 'Image of the Year' Award. With the contest theme, "invisible to visible," this year featured diabetic retinopathy (DR) cases which often require examination of the fovea to the extreme periphery. Eye care pr
- Lenz Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trialshttps://modernod.com/news/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/2482207/Lenz Therapeutics announced positive topline results from its phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. In phase 3 safety and efficacy trials (CLARITY 1 and 2), our lead product candidate LNZ100 (1.75% ac
- West Point Optical Group and Verséa Ophthalmics Announce Partnership Supply Agreement for Biovance and Biovance 3L Ocularhttps://modernod.com/news/west-point-optical-group-and-versea-ophthalmics-announce-partnership-supply-agreement-for-biovance-and-biovance-3l-ocular/2482206/West Point Optical Group (WPOG), which operates 86 Pearle Vision stores, and Verséa Ophthalmics announced that the companies have entered into a partnership supply agreement in which Verséa will be the exclusive provider of its Biovance and Biovance 3L Ocular pro
- Sight Sciences Announces the Results of the 3-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCThttps://modernod.com/news/sight-sciences-announces-the-results-of-the-3-year-prospective-gemini-trial-and-the-cross-over-phase-of-the-sahara-rct/2482205/Sight Sciences announced that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System, will be presented in two oral presentations and two posters at this year’s ASCRS annual meeting, April 5-8, 
- Viatris Announces US Launch of Ryzumvi for the Reversal of Mydriasishttps://modernod.com/news/viatris-announces-us-launch-of-ryzumvi-for-the-reversal-of-mydriasis/2482191/Viatris and Ocuphire announced the US commercial launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the Uni
- Bausch + Lomb to Present New Scientific Data and Analyses at the ASCRS Annual Meetinghttps://modernod.com/news/bausch-lomb-to-present-new-scientific-data-and-analyses-at-the-ascrs-annual-meeting/2482190/Bausch + Lomb announced 15 podium and four poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS)
- Aurion Biotech Announces First Canadian Subject Dosed in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-first-canadian-subject-dosed-in-phase-1-2-clinical-trial/2482189/Aurion Biotech announced that it has dosed the first Canadian subject in its phase 1/2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d